A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Completed · Phase 2 · Has a placebo group

Conditions studied: Acne Inversa

In brief

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Key facts

Study ID

NCT04092452

Run by

Pfizer

People needed

194

Starts

2019-12-02

Expected to finish

2022-01-10

Last updated by the study team

2023-06-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa

You may not qualify if…

• History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
• Infected with hepatitis B or hepatitis C viruses.
• Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Where it is running

• The University of Alabama at Birmingham Hospital Outreach Lab — Birmingham, Alabama, United States
• The University of Alabama at Birmingham Investigation Drug Services Pharmacy — Birmingham, Alabama, United States
• The University of Alabama at Birmingham — Birmingham, Alabama, United States
• Mayo Clinic — Scottsdale, Arizona, United States
• Center for Dermatology Clinical Research, Inc. — Fremont, California, United States
• Pacific Clinical Trials — Long Beach, California, United States
• Keck School of Medicine of University of Southern California — Los Angeles, California, United States
• UCSF Dermatology Clinic — San Francisco, California, United States
• University of California San Francisco — San Francisco, California, United States
• UCSF Psoriasis and Skin Treatment Center — San Francisco, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• New England Research Associates, LLC — Bridgeport, Connecticut, United States
• Dermatology Physicians of Connecticut — Shelton, Connecticut, United States
• Total Dermatology Care Center — Jacksonville, Florida, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• Olympian Clinical Research Largo Office — Largo, Florida, United States
• University of Miami Hospital — Miami, Florida, United States
• Tory Sullivan MD PA — North Miami Beach, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• MidState Skin Institute — Ocala, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Leavitt Medical Associates of Florida d/b/a Ameriderm Research — Ormond Beach, Florida, United States
• Riverchase Dermatology and Cosmetic Surgery — Pembroke Pines, Florida, United States
• The University Of Alabama At Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.